Inhibikase Therapeutics (IKT) EBT Margin Growth (1y) (2021 - 2023)
Powered by 
Analysis
Inhibikase Therapeutics (IKT) EBT Margin Growth (1y) (2021 - 2023) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -153.00 |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -571.00 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 553.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 4,709.00 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1,076.00 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1,911.00 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -392.00 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 29,565.00 |
| 10 | Inhibikase Therapeutics | 435.56 Mn | 276.54 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | -44.03 Bn |
| Sep 30, 2023 | 5.57 Mn |
| Jun 30, 2023 | 6.55 Mn |
| Mar 31, 2023 | 277,385.00 |
| Dec 31, 2022 | 25.25 Mn |
| Sep 30, 2022 | -6.03 Mn |
| Jun 30, 2022 | -7.06 Mn |
| Mar 31, 2022 | -989,407.00 |
| Dec 31, 2021 | -25.86 Mn |
| Sep 30, 2021 | 41,846.00 |
| Jun 30, 2021 | -128.00 |
| Mar 31, 2021 | 1,476.00 |